NorthWest Biotherapeutics Inc (NWBO)

[AVII77]

DCVax’s selection criteria is on par with all other GBM trials

No, it is not.

The DCVax trial assessed patients progression after completion of chemorad. If not progressing they could be randomized.

Most P3 GBM trials randomize earlier, before chemorad.
Avaglio, RTOG 0825, Checkmate 548, Checkmate 498, the "Dose Dense" Trial, the Centric trial. (Someone tell me again why it isnt feasible to perform a large RCT in nGBM)

Now, OPTUNE was tested in the maintenance setting, like DCVax. But, unlike the DCVax trial, they randomized patients whose GBM was only amenable to biopsy. Biopsy only patients have a far far worse prognosis.

Also, the Rindo study was tested in a maintenance setting. Like Optune (and DCVax) they screened patients for progression after chemorad. (Madingly, even though their paper says the protocol is available, they never published it as a supplemental appendix so we don't know how they did the assessment).

But for the Rindo study, all patients were EGFR+. In all other cancers, EGFR amplification is a negative prognostic factor. (There is, admittedly, some debate about what it means for GBM.)

So, tell me again how the "selection criteria is on par" with other GBM trials. It most certainly is not.